An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines

ConclusionsAdditional evidence is needed for vulnerable populations (e.g., childhood cancer survivors) who are at high risk for human papillomavirus vaccine-related cancers and, therefore, may be more cost effective when receiving human papillomavirus vaccines. Quantifying human papillomavirus vaccine cost effectiveness via meta-analyses is feasible if investigators can increase the homogeneity of their populations.

http://link.springer.com/10.1007/s40261-022-01155-5

Source: Clinical Drug Investigation - April 30, 2022 Category: Drugs & Pharmacology Source Type: research